Qualcomm will appeal the US$773 million fine it received from the Taiwan Fair Trade Commission (TFTC) on Wednesday, October 11, the San Diego, California-based semiconductor manufacturer said shortly after yet another competition watchdog concluded that the company employed monopolistic business practices. The firm is now in the process of assessing its options and will file to stay any sanctions set to follow as a result of the TFTC’s decision while it’s in the process of appealing the verdict that it strongly disagrees with, according to the tech giant’s statement on the matter.
The appeal process itself has yet to be initiated by Qualcomm as the firm requires an official decision from the TFTC before it’s able to legally challenge it, with its attorneys expecting the government agency to provide it with the ruling in the coming weeks, presumably by early November.
The maker of Snapdragon-series chips didn’t go into many details regarding the contents of the ruling itself but based its disagreement on the fact that there is “no rational relationship” between the severity of the TFTC’s fine and the level of revenue Qualcomm records in the Far Eastern country, adding that the size of its Taiwanese operations also couldn’t be used as the basis for a historic fine issued by the agency. Due to that belief, the company is adamant to specifically appeal the method used by the TFTC to calculate the fine, as well as the amount of the fine itself.
Full Content: NBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas